Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Retinal stem cell therapy - jCyte

Next Previous
Drug Profile

Retinal stem cell therapy - jCyte

Alternative Names: hRPC - jCyte; Human retinal progenitor cell therapy - jCyte; Human retinal progenitor cells - jCyte; jCell; jCell therapy - jCyte

Latest Information Update: 23 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator jCyte
  • Developer California Institute for Regenerative Medicine; jCyte
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinitis pigmentosa
  • New Molecular Entity No

Highest Development Phases

  • Phase II Retinitis pigmentosa
  • Preclinical Diabetic retinopathy; Dystrophy; Glaucoma; Optic nerve disorders

Most Recent Events

  • 21 Feb 2024 US FDA reviews the planned phase II/III tria l design and approves the primary endpoint and the two jCell doses to be included in the trial
  • 21 Feb 2024 jCyte plans a phase II/III pivotal trial for Retinitis pigmentosa (Intravitreous) in second half of 2024
  • 22 Mar 2022 jCyte in collaboration with California Institute for Regenerative Medicine (CIRM) completes a phase II trial in Retinitis pigmentosa (Treatment-experienced) in USA (Intravitreal, Injection) (NCT04604899)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top